Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy - Report - MDSpire

Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy

  • By

  • Yanlin Zhong

  • Yiming Hu

  • Yuan Lin

  • Huping Wu

  • June 15, 2026

  • 0 min

Share

Clinical Report: AI-Enhanced Risk Stratification for Targeted Chalazion Management

Overview

This study evaluates the efficacy of intralesional triamcinolone acetonide (TA), intense pulsed light (IPL), and their combination in managing chalazion recurrence. A hybrid AI-clinical model was developed to enhance risk stratification and predict recurrence rates more accurately.

Background

Chalazion is a common eyelid disorder that can lead to significant ocular discomfort and visual disturbances. Understanding the factors influencing chalazion recurrence is crucial for optimizing treatment strategies, particularly in high-risk populations. This study introduces an AI-enhanced model to improve prediction and management of chalazion recurrence.

Data Highlights

Group3-Month Resolution RateRecurrence Rate
TA + IPL95.2%8.3%
TA Only90.8%15.4%
IPL Only79.4%38.2%

Key Findings

  • The combined TA + IPL group showed a significantly higher resolution rate (95.2%) compared to TA-only (90.8%) and IPL-only (79.4%) groups (p < 0.001).
  • Recurrence rates were significantly different among groups: IPL (38.2%), TA (15.4%), and TA + IPL (8.3%) (χ2 = 31.73, p < 0.001).
  • Demodex infection, age, chronicity, and meibomian gland dysfunction were identified as independent risk factors for recurrence.
  • The hybrid AI-clinical model achieved an AUC of 0.822, outperforming clinical and XGBoost models (p < 0.05).
  • AI integration refined risk estimates with a net reclassification improvement (NRI) of 0.365 (p < 0.001).
  • In high-risk patients, recurrence rates with monotherapy ranged from 83.3% to 91.7%, while combined therapy reduced this to 60.0%.

Clinical Implications

The findings suggest that combined TA + IPL therapy may be more effective in reducing chalazion recurrence, particularly in high-risk patients. The AI-enhanced risk stratification model can assist clinicians in making informed treatment decisions.

Conclusion

The study demonstrates that a hybrid AI-clinical model can significantly improve predictions of chalazion recurrence, highlighting the efficacy of combined TA + IPL therapy in managing this condition.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Intralesional Vitamin D versus Triamcinolone Acetonide for the Treatment of Keloids: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  2. Contact Lens Spectrum, 2010 -- Treatment Plan
  3. Ophthalmology Management, 2026 -- Adding Interventional DED Treatment to Your Practice
  4. Retinal Physician, 2010 -- Peer-Reviewed: Intraocular Pressure Changes After Removal of Sub-Tenon’s Triamcinolone Acetonide Depot
  5. BMJ Best Practice -- Stye and chalazion - Symptoms, diagnosis and treatment
  6. ScienceDirect -- Intralesional Triamcinolone Acetonide Injection Versus Incision and Curettage for Primary Chalazia: A Prospective, Randomized Study
  7. Scientific Reports -- Therapeutic effect of intense pulsed light on different types of chalazion in children
  8. Stye and chalazion - Symptoms, diagnosis and treatment | BMJ Best Practice US
  9. Intralesional Triamcinolone Acetonide Injection Versus Incision and Curettage for Primary Chalazia: A Prospective, Randomized Study - ScienceDirect
  10. Therapeutic effect of intense pulsed light on different types of chalazion in children | Scientific Reports

Original Source(s)

Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy

  • by Yanlin Zhong, Yiming Hu, Yuan Lin, Huping Wu

  • June 15, 2026

Related Content

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

  • January 14, 2026

  • 3 min
Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

Addressing the Corneal Nerves in DED Care

Think of treating DED as a marathon, not a sprint. If we pace ourselves and find the right points to intervene at the outset, we can often forestall the tissue damage, nerve dysfunction, and frustrations associated with longstanding DED.